Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier) [Corrigendum]

This article refers to:

Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier)

Casadei-Gardini A, Montagnani F, Casadei C, et al. Cancer Manag Res. 2019;11:3631–3642.

The authors have advised that the affiliations are not correct in the published paper (page 3631). They have provided revised author and affiliations lists, as follows, and confirm that the modifications do not alter their conflicts of interest status in regard to this work.

Andrea Casadei-Gardini,^1,2 Francesco Montagnani,³ Chiara Casadei,¹ Francesca Arcadipane,⁴ Kalliopi Andrikou,² Deborah Aloi,⁵ Alessandra Anna Prete,⁶ Maria Giulia Zampino,⁷ Antonella Argentiero,⁸ Giuseppe Pugliese,² Stefania Martini,⁴ Giuseppe Carlo Iorio,⁴ Mario Scartozzi,⁹ Massimiliano Mistrangelo,¹⁰ Lorenzo Fornaro,¹¹ Paola Cassoni,¹² Giorgia Marisi,¹³ Veronica Dell’Acqua,¹⁴ Paola Simona Ravenda,⁷ Sara Lonardi,⁶ Nicola Silvestris,⁸ Berardino De Bari,⁵ Umberto Ricardi,⁴ Stefano Cascinu,² Pierfrancesco Franco⁴

¹Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy; ²Department of Hematology and Oncology, University of Modena and Reggio Emilia, Modena, Italy; ³Oncology Department, SOC Oncology, ASL (Health Local Authority), Biella, Italy; ⁴Department of Oncology, Radiation Oncology, University of Turin, Turin, Italy; ⁵Radiation Oncology Department, Centre Hospitalier Régional Universitaire “Jean Minjoz”, Besançon Cedex, France; ⁶Unit of Medical Oncology 1, Department of Clinical and Experimental Oncology, Istituto Oncologico Veneto, IRCCS, Padua, Italy; ⁷Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology, IRCCS, Milan, Italy; ⁸Medical Oncology Unit, Cancer Institute Giovanni Paolo II, Bari, Italy; ⁹Department of Medical Oncology, University of Cagliari, Cagliari, Italy; ¹⁰Department of Surgical Sciences, University of Turin, Turin, Italy; ¹¹Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana University, Pisa, Italy; ¹²Department of Medical Sciences, Pathology Unit, University of Turin, Turin, Italy; ¹³Biosciences Laboratory, Istituto Scientifico Romagnolo per Lo Studio e La Cura Dei Tumori (IRST) IRCCS, Meldola, Italy; ¹⁴Department of Radiotherapy, IRCCS, European Institute of Oncology, Milan, Italy